Delving into the Latest Updates on Anergis SA with Synapse

A MULTICENTRE, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL TO ASSESS THE EFFICACY AND TOLERABILITY OF TWO DOSING REGIMENS OF ALLERT, A COMBINATION OF CONTIGUOUS OVERLAPPING PEPTIDES DERIVED FROM BET V 1, IN ADULTS WITH BIRCH POLLEN ALLERGIC RHINITIS/RHINOCONJUNCTIVITIS

开始日期2016-11-03

申办/合作机构

Anergis SA

NCT02943720

/ Completed临床2期

A Multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and Tolerability of Two Dosing Regimens of AllerT in Adults With Birch Pollen Allergic Rhinitis

A multicentre, Double-blind, Placebo-Controlled, Randomized Trial to Assess the Efficacy and Tolerability of Two Dosing Regimens of AllerT, a Combination of Contiguous Overlapping Peptides Derived from Bet v 1, in Adults with Birch Pollen Allergic Rhinitis/Rhinoconjunctivitis

开始日期2016-09-01

申办/合作机构

Anergis SA

NCT02271009

/ Completed临床2期

A Double-Blind, Placebo-Controlled, Randomized Trial to Compare the Efficacy and Tolerability of Three Dose Regimens of AllerT, in Adults With Allergic Rhino-Conjunctivitis to Birch Pollen Studied in Environmental Exposure Chamber

The purpose of this study is to find the optimal dose of AllerT that should be used to treat moderate to severe allergies due to birch tree pollen.
There are 4 treatment groups in this study; 3 treatment groups will receive AllerT at different doses and 1 treatment group will receive placebo.
This study will also assess the effectiveness and safety of AllerT compared to placebo in relieving allergy symptoms.

开始日期2014-10-01

申办/合作机构

Anergis SA

[+1]

100 项与 Anergis SA 相关的临床结果

登录后查看更多信息

0 项与 Anergis SA 相关的专利（医药）

登录后查看更多信息

100 项与 Anergis SA 相关的药物交易

登录后查看更多信息

100 项与 Anergis SA 相关的转化医学

登录后查看更多信息